Dr. Alissa Visram on the presented the data during 65th American Society of Hematology Annual Meeting. Patients with multiple myeloma who were treated in the real world had 44% worse progression-free survival and 75% worse overall survival than patients treated on clinical trials, according to a pooled analysis of efficacy versus effectiveness for seven MM regimens.

Video: https://medicaldigest.org/scientific-contents/interview:dramatically-worse-myeloma-outcomes-real-world-vs-trials

Professor Marlise R. Luskin summarizes the state of the art acute lymphoblastic leukemia treatement at the 65th American Society of Hematology Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:state-art-all-treatement-2023

Professor Agnieszka Wierzbowska summarizes the most important highlights in the field of acute myeloid leukemia treatment at the 65th American Society of Hematology Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:acute-myeloid-leukemia-highlights-ash-2023-congress

Professor Enrique Ocio summarizes the diagnostic and therapeutic novelties of Multiple Myeloma management at the 65th American Society of Hematology Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:diagnostic-and-therapeutic-novelties-multiple-myeloma-management

Professor Umberto Vitolo summarizes the most important highlights in the field of Non-Hodgkin Lymphoma treatment at the 65th American Society of Hematology Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:non-hodgkin-lymphoma-highlights-ash-2023-congress

Professor Pieter Sonneveld explains that newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone showed significantly higher rates of survival without disease progression compared with those who received VRd alone. Results from the phase III Perseus trial were reported at the 2023 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-outperforms-vrd-alone-multiple-myeloma

Professor Ibrahim Aldoss explains that patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene, a genetic marker known as KMT2Ar, who were treated with revumenib saw an overall response rate of 63%, according to results from a phase II trial being reported during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

Video: https://medicaldigest.org/scientific-contents/interview:revumenib-found-effective-against-high-risk-kmt2ar-acute-leukemia

Professor Mazyar Shadman on the findings from a real-world, retrospective study that were presented during the 2023 ASH Annual Meeting: Autologous hematopoietic cell transplantation lowered relapse and progression rates and improved survival outcomes vs CAR T-cell therapy in patients with relapsed large B-cell lymphoma who experienced complete remission with interim treatment.

Video: https://medicaldigest.org/scientific-contents/interview:auto-hct-improves-pfs-relapse-rates-relapsed-lbcl-subset-during-complete-response

Professor Peter Hillmen on the combination of ibrutinib and venetoclax, at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia, according to findings from the phase 3 FLAIR trial that were presented at the 2023 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:ibrutinib-plus-venetoclax-mrd-directed-duration-treatment-superior-fcr-and-new-standard-care-previously-untreated-cll

Professor Andrew Srisuwananukorn's research revealed that an AI-powered machine learning algorithm, when examining digital whole-slide images of diagnostic bone marrow biopsies, accurately distinguished between prefibrotic primary myelofibrosis and essential thrombocythemia with an 92.3% accuracy rate, according to data presented at the 2023 ASH Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:interpretable-artificial-intelligence-differentiates-prefibrotic-primary-myelofibrosis-essential-thrombocythemia